These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 9110450)

  • 21. Iris vasculopathy in galactose-fed rats.
    Caspers-Velu LE; Wadhwani KC; Rapoport SI; Kador PF
    Exp Eye Res; 1999 Feb; 68(2):211-21. PubMed ID: 10068486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pharmacology of aldose reductase inhibitors.
    Kador PF; Robison WG; Kinoshita JH
    Annu Rev Pharmacol Toxicol; 1985; 25():691-714. PubMed ID: 3923907
    [No Abstract]   [Full Text] [Related]  

  • 23. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy.
    Sun W; Oates PJ; Coutcher JB; Gerhardinger C; Lorenzi M
    Diabetes; 2006 Oct; 55(10):2757-62. PubMed ID: 17003340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Berberine inhibits aldose reductase and oxidative stress in rat mesangial cells cultured under high glucose.
    Liu W; Liu P; Tao S; Deng Y; Li X; Lan T; Zhang X; Guo F; Huang W; Chen F; Huang H; Zhou SF
    Arch Biochem Biophys; 2008 Jul; 475(2):128-34. PubMed ID: 18471986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of aldose reductase inhibitors in diabetic complications: recent trends.
    Kaul CL; Ramarao P
    Methods Find Exp Clin Pharmacol; 2001 Oct; 23(8):465-75. PubMed ID: 11838322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New approaches for treatment in diabetes: aldose reductase inhibitors.
    Hotta N
    Biomed Pharmacother; 1995; 49(5):232-43. PubMed ID: 7579002
    [No Abstract]   [Full Text] [Related]  

  • 27. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications.
    Yabe-Nishimura C
    Pharmacol Rev; 1998 Mar; 50(1):21-33. PubMed ID: 9549756
    [No Abstract]   [Full Text] [Related]  

  • 28. Design and synthesis of highly potent and selective (2-arylcarbamoyl-phenoxy)-acetic acid inhibitors of aldose reductase for treatment of chronic diabetic complications.
    Van Zandt MC; Sibley EO; McCann EE; Combs KJ; Flam B; Sawicki DR; Sabetta A; Carrington A; Sredy J; Howard E; Mitschler A; Podjarny AD
    Bioorg Med Chem; 2004 Nov; 12(21):5661-75. PubMed ID: 15465344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of aldose reductase inhibition on the microvascular reactivity in experimental diabetes.
    Fortes ZB; Becker C; Oliveira MA; Scivoletto R
    Gen Pharmacol; 1996 Jul; 27(5):917-21. PubMed ID: 8842700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aldose Reductase: An Emerging Target for Development of Interventions for Diabetic Cardiovascular Complications.
    Jannapureddy S; Sharma M; Yepuri G; Schmidt AM; Ramasamy R
    Front Endocrinol (Lausanne); 2021; 12():636267. PubMed ID: 33776930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel zwitterionic inhibitor of aldose reductase interferes with polyol pathway in ex vivo and in vivo models of diabetic complications.
    Karasova MJ; Prnova MS; Stefek M
    Pharmazie; 2014 Oct; 69(10):747-51. PubMed ID: 25985564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review.
    Schemmel KE; Padiyara RS; D'Souza JJ
    J Diabetes Complications; 2010; 24(5):354-60. PubMed ID: 19748287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.
    Van Zandt MC; Jones ML; Gunn DE; Geraci LS; Jones JH; Sawicki DR; Sredy J; Jacot JL; Dicioccio AT; Petrova T; Mitschler A; Podjarny AD
    J Med Chem; 2005 May; 48(9):3141-52. PubMed ID: 15857120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular complications of diabetes mellitus.
    Yuan S; Liu Y; Zhu L
    Clin Exp Pharmacol Physiol; 1999 Dec; 26(12):977-8. PubMed ID: 10626065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aldose reductase inhibitors.
    Kirchain WR; Rendell MS
    Pharmacotherapy; 1990; 10(5):326-36. PubMed ID: 2122421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [State of the microcirculation in diabetes mellitus (based on conjunctival biomicroscopic data)].
    Golubiatnikova GA; Sokolovskiĭ GA; Kukes VG; Abylaev Zh; Timakina AP; Podgornaia NN
    Sov Med; 1978 Jun; (6):41-7. PubMed ID: 675346
    [No Abstract]   [Full Text] [Related]  

  • 37. Polymorphisms of the aldose reductase gene and susceptibility to diabetic microvascular complications.
    Demaine AG
    Curr Med Chem; 2003 Aug; 10(15):1389-98. PubMed ID: 12871136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discoveries in research on diabetic keratopathy.
    Cisarik-Fredenburg P
    Optometry; 2001 Nov; 72(11):691-704. PubMed ID: 12363257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new approach against sugar cataract through aldose reductase inhibitors.
    Banditelli S; Boldrini E; Vilardo PG; Cecconi I; Cappiello M; Dal Monte M; Marini I; Del Corso A; Mura U
    Exp Eye Res; 1999 Nov; 69(5):533-8. PubMed ID: 10548473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of an aldose reductase inhibitor on lens metabolism, ATPases and antioxidative defense in streptozotocin-diabetic rats: an intervention study.
    Obrosova IG; Fathallah L
    Diabetologia; 2000 Aug; 43(8):1048-55. PubMed ID: 10990083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.